| Name | Title | Contact Details |
|---|
Fifth Eye`s early warning system continuously forecasts patient trajectory, giving doctors and nurses a heads up about impending trouble hours in advance of other methods.
Vericred, Inc. is a healthcare data services company, operating at the intersection of health insurance and technology. Vericred serves companies who are transforming today`s healthcare experience, from care management to finding the right insurance plan. Its datasets are the foundation on which the healthcare industry builds innovative solutions. Vericred`s health insurance data platform, which is comprised of plan design and rate data, provider-network data and formulary data, offers a solution to an industry plagued by highly fragmented, rapidly changing data that currently exists in non-standard and non-structured formats.
AnazaoHealth Corporation is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Tampa, FL. To find more information about AnazaoHealth Corporation, please visit www.anazaohealth.com
Improving health is at the heart of Greenway Health`s work. We connect providers to the right information and insights, at the right place and time, so they can make patient-driven care a reality while navigating the ever-changing healthcare system. Greenway delivers exceptional service through a deep team of clinical, financial, and technology experts committed to innovations that keep people healthier and happier. We partner with over 8,000 organizations and 75,000 progressive providers across more than 40 specialties, which translates into more than 100 million lives that are touched by our solutions. All of Greenway Health`s solutions and services are designed to meet our company-wide goals of serving physicians, connecting the industry, and empowering better care. Whether as a customer, strategic partner, or staff member, you are invited to partner with us to create a smarter healthcare system.
SCYNEXIS, Inc. is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. Our scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery and development of innovative medicines over a broad range of therapy areas. We are developing our lead product candidate, SCY-078, a novel antifungal in Phase 2, as a novel oral and intravenous drug for the treatment of serious and life-threatening invasive fungal infections in humans.